Immune Checkpoint-Mediated Interactions Between Cancer and Immune Cells in Prostate Adenocarcinoma and Melanoma

Overview

Journal Front Immunol

Specialty Allergy & Immunology

Date 2018 Aug 16

PMID 30108594

Citations 18

Authors

Angela Rita Elia

Sara Caputo

Matteo Bellone

Affiliations

Soon will be listed here.

Abstract

Prostate adenocarcinoma (PCa) and melanoma are paradigmatic examples of tumors that are either poorly or highly sensitive to therapies based on monoclonal antibodies directed against regulatory pathways in T lymphocytes [i.e., immune checkpoint blockade (ICB)]. Yet, approximately 40% of melanoma patients are resistant or acquire resistance to ICB. What characterize the microenvironment of PCa and ICB-resistant melanoma are a scanty cytotoxic T cell infiltrate and a strong immune suppression, respectively. Here, we compare the tumor microenvironment in these two subgroups of cancer patients, focusing on some among the most represented immune checkpoint molecules: cytotoxic T lymphocyte-associated antigen-4, programmed death-1, lymphocyte activation gene-3, and T cell immunoglobulin and mucin-domain containing-3. We also report on several examples of crosstalk between cancer and immune cells that are mediated by inhibitory immune checkpoints and identify promising strategies aimed at overcoming ICB resistance both in PCa and melanoma.

Citing Articles

Tumor Microenvironment as a Therapeutic Target in Melanoma Treatment.

Kharouf N, Flanagan T, Hassan S, Shalaby H, Khabaz M, Hassan S Cancers (Basel). 2023; 15(12).

PMID: 37370757 PMC: 10296288. DOI: 10.3390/cancers15123147.

Gene-guided OX40L anchoring to tumor cells for synergetic tumor "self-killing" immunotherapy.

Lin L, Hu Y, Guo Z, Chen J, Sun P, Tian H Bioact Mater. 2023; 25:689-700.

PMID: 37056266 PMC: 10086763. DOI: 10.1016/j.bioactmat.2022.07.008.

Randomized phase II trial in prostate cancer with hormone-sensitive OligometaSTatic relapse: Combining stereotactic ablative radiotherapy and durvalumab (POSTCARD GETUG P13): Study protocol.

Roge M, Pointreau Y, Sargos P, Meyer E, Schick U, Hasbini A Clin Transl Radiat Oncol. 2023; 40:100613.

PMID: 36968576 PMC: 10034400. DOI: 10.1016/j.ctro.2023.100613.

Progression in immunotherapy for advanced prostate cancer.

Liang H, Liu Y, Guo J, Dou M, Zhang X, Hu L Front Oncol. 2023; 13:1126752.

PMID: 36925917 PMC: 10011447. DOI: 10.3389/fonc.2023.1126752.

Immunoproteasome inhibition prevents progression of castration-resistant prostate cancer.

Li J, Liu N, Zhou H, Xian P, Song Y, Tang X Br J Cancer. 2023; 128(7):1377-1390.

PMID: 36681728 PMC: 10050322. DOI: 10.1038/s41416-022-02129-2.

References

Nakayama M, Akiba H, Takeda K, Kojima Y, Hashiguchi M, Azuma M . Tim-3 mediates phagocytosis of apoptotic cells and cross-presentation. Blood. 2009; 113(16):3821-30. DOI: 10.1182/blood-2008-10-185884. View

Bellone M, Calcinotto A, Corti A . Won't you come on in? How to favor lymphocyte infiltration in tumors. Oncoimmunology. 2012; 1(6):986-988. PMC: 3489769. DOI: 10.4161/onci.20213. View

Huang Y, Zhu C, Kondo Y, Anderson A, Gandhi A, Russell A . CEACAM1 regulates TIM-3-mediated tolerance and exhaustion. Nature. 2014; 517(7534):386-90. PMC: 4297519. DOI: 10.1038/nature13848. View

Melero I, Berman D, Aznar M, Korman A, Perez Gracia J, Haanen J . Evolving synergistic combinations of targeted immunotherapies to combat cancer. Nat Rev Cancer. 2015; 15(8):457-72. DOI: 10.1038/nrc3973. View

Elia A, Grioni M, Basso V, Curnis F, Freschi M, Corti A . Targeting Tumor Vasculature with TNF Leads Effector T Cells to the Tumor and Enhances Therapeutic Efficacy of Immune Checkpoint Blockers in Combination with Adoptive Cell Therapy. Clin Cancer Res. 2018; 24(9):2171-2181. DOI: 10.1158/1078-0432.CCR-17-2210. View

Jachetti E, Caputo S, Mazzoleni S, Brambillasca C, Parigi S, Grioni M . Tenascin-C Protects Cancer Stem-like Cells from Immune Surveillance by Arresting T-cell Activation. Cancer Res. 2015; 75(10):2095-108. DOI: 10.1158/0008-5472.CAN-14-2346. View

Hannier S, Tournier M, Bismuth G, Triebel F . CD3/TCR complex-associated lymphocyte activation gene-3 molecules inhibit CD3/TCR signaling. J Immunol. 1998; 161(8):4058-65. View

Daud A, Loo K, Pauli M, Sanchez-Rodriguez R, Munoz Sandoval P, Taravati K . Tumor immune profiling predicts response to anti-PD-1 therapy in human melanoma. J Clin Invest. 2016; 126(9):3447-52. PMC: 5004965. DOI: 10.1172/JCI87324. View

Knapp J, Lokeshwar S, Vogel U, Hennenlotter J, Schwentner C, Kramer M . Galectin-3 expression in prostate cancer and benign prostate tissues: correlation with biochemical recurrence. World J Urol. 2012; 31(2):351-8. DOI: 10.1007/s00345-012-0925-y. View

10.

Callahan M, Postow M, Wolchok J . Targeting T Cell Co-receptors for Cancer Therapy. Immunity. 2016; 44(5):1069-78. DOI: 10.1016/j.immuni.2016.04.023. View

11.

Pires da Silva I, Gallois A, Jimenez-Baranda S, Khan S, Anderson A, Kuchroo V . Reversal of NK-cell exhaustion in advanced melanoma by Tim-3 blockade. Cancer Immunol Res. 2014; 2(5):410-22. PMC: 4046278. DOI: 10.1158/2326-6066.CIR-13-0171. View

12.

Hemon P, Jean-Louis F, Ramgolam K, Brignone C, Viguier M, Bachelez H . MHC class II engagement by its ligand LAG-3 (CD223) contributes to melanoma resistance to apoptosis. J Immunol. 2011; 186(9):5173-83. DOI: 10.4049/jimmunol.1002050. View

13.

Chen T, Razak A, Bedard P, Siu L, Hansen A . A systematic review of immune-related adverse event reporting in clinical trials of immune checkpoint inhibitors. Ann Oncol. 2015; 26(9):1824-1829. DOI: 10.1093/annonc/mdv182. View

14.

Ariyan C, Brady M, Siegelbaum R, Hu J, Bello D, Rand J . Robust Antitumor Responses Result from Local Chemotherapy and CTLA-4 Blockade. Cancer Immunol Res. 2018; 6(2):189-200. PMC: 6857638. DOI: 10.1158/2326-6066.CIR-17-0356. View

15.

Clark C, Gupta H, Sareddy G, Pandeswara S, Lao S, Yuan B . Tumor-Intrinsic PD-L1 Signals Regulate Cell Growth, Pathogenesis, and Autophagy in Ovarian Cancer and Melanoma. Cancer Res. 2016; 76(23):6964-6974. PMC: 5228566. DOI: 10.1158/0008-5472.CAN-16-0258. View

16.

Han G, Chen G, Shen B, Li Y . Tim-3: an activation marker and activation limiter of innate immune cells. Front Immunol. 2013; 4:449. PMC: 3857553. DOI: 10.3389/fimmu.2013.00449. View

17.

Huang A, Postow M, Orlowski R, Mick R, Bengsch B, Manne S . T-cell invigoration to tumour burden ratio associated with anti-PD-1 response. Nature. 2017; 545(7652):60-65. PMC: 5554367. DOI: 10.1038/nature22079. View

18.

Jardim D, Gagliato D, Giles F, Kurzrock R . Analysis of Drug Development Paradigms for Immune Checkpoint Inhibitors. Clin Cancer Res. 2017; 24(8):1785-1794. PMC: 5899646. DOI: 10.1158/1078-0432.CCR-17-1970. View

19.

Gordon-Alonso M, Hirsch T, Wildmann C, van der Bruggen P . Galectin-3 captures interferon-gamma in the tumor matrix reducing chemokine gradient production and T-cell tumor infiltration. Nat Commun. 2017; 8(1):793. PMC: 5630615. DOI: 10.1038/s41467-017-00925-6. View

20.

Xu F, Liu J, Liu D, Liu B, Wang M, Hu Z . LSECtin expressed on melanoma cells promotes tumor progression by inhibiting antitumor T-cell responses. Cancer Res. 2014; 74(13):3418-28. DOI: 10.1158/0008-5472.CAN-13-2690. View